Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11472791 Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

Patent 11472791 was granted and assigned to Incyte on October, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Zhenwu Li0

Jingwei Li0

Ding-Quan Qian0

Fenglei Zhang0

Jeffrey C. Yang0

Joshua Hummel0

Kaijiong Xiao0

Liangxing Wu0

...

Date of Patent

October 18, 2022

0

Patent Application Number

168092180

Date Filed

March 4, 2020

0

Patent Citations

US Patent 11066404 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors

US Patent 10308644 Heterocyclic compounds as immunomodulators

Patent Citations Received

US Patent 11976073 Bicyclic amines as CDK2 inhibitors

0

US Patent 11919904 Sulfonylamide compounds as CDK2 inhibitors

0

US Patent 11866432 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors

0

US Patent 11981671 Bicyclic pyrazolyl amines as CDK2 inhibitors

0

US Patent 11851426 Bicyclic amines as CDK2 inhibitors

0

Patent Primary Examiner

0

CPC Code

0

The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11472791 Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool